WEST CHESTER, Ohio, April 18 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the first quarter ended March 31, 2008 on Tuesday, May 6, 2008.
AtriCure will host a conference call at 10:00 a.m. ET on Tuesday, May 6, 2008 to discuss first quarter 2008 results. A live web cast of the conference call will be available online from the investor relations page of AtriCure's corporate web site at http://www.atricure.com.
Pre-registration is available for this call at the following URL:
Pre-registering is not mandatory but is recommended as it will provide you immediate entry into the call and will facilitate the timely start of the conference. Pre-registration only takes a few moments and you may pre-register at any time, including up to and after the call start time. Alternatively, if you prefer being placed into the call by an operator, please call (888) 713-4215 for domestic callers and (617) 213-4867 for international callers at least 15 minutes prior to the call start time and use reservation number 74210586.
The web cast will remain available on AtriCure's web site through June 6, 2008. A telephonic replay of the call will also be available until June 6, 2008. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Please use reservation code 90053061.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator(R) system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator(R) bipolar ablation system,
including its Isolator Synergy(TM) ablation clamps, and AtriCure's
multifunctional and linear ablation pens, for the ablation, or destruction,
of cardiac tissue during surgical procedures. Additionally, the FDA has
cleared AtriCure's multifunctional pen for temporary pacing, sensing,
stimulating and recording during the evaluation of cardiac arrhythmias. To
date, the FDA has not cleared or approved AtriCure's products for the
treatment of AF. AtriCure's left atrial appendage clip system has not been
approved for commercial use. It is currently being used in clinical
evaluations in Europe.
Julie A. Piton
Vice President and Chief Financial Officer
|SOURCE AtriCure, Inc.|
Copyright©2008 PR Newswire.
All rights reserved